164 related articles for article (PubMed ID: 19949319)
1. The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users.
Lile JA; Kelly TH; Hays LR
Behav Pharmacol; 2010 Feb; 21(1):29-38. PubMed ID: 19949319
[TBL] [Abstract][Full Text] [Related]
2. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
Lile JA; Kelly TH; Pinsky DJ; Hays LR
Psychopharmacology (Berl); 2009 Apr; 203(2):241-50. PubMed ID: 19018520
[TBL] [Abstract][Full Text] [Related]
3. Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC.
Lile JA; Kelly TH; Hays LR
Drug Alcohol Depend; 2014 Oct; 143():141-8. PubMed ID: 25124305
[TBL] [Abstract][Full Text] [Related]
4. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans.
Rush CR; Kollins SH; Pazzaglia PJ
Exp Clin Psychopharmacol; 1998 Feb; 6(1):32-44. PubMed ID: 9526144
[TBL] [Abstract][Full Text] [Related]
5. An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults.
Kollins SH; Schoenfelder EN; English JS; Holdaway A; Van Voorhees E; O'Brien BR; Dew R; Chrisman AK
J Subst Abuse Treat; 2015 Jan; 48(1):96-103. PubMed ID: 25175495
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in the subjective effects of oral Δ
Fogel JS; Kelly TH; Westgate PM; Lile JA
Pharmacol Biochem Behav; 2017 Jan; 152():44-51. PubMed ID: 26780348
[TBL] [Abstract][Full Text] [Related]
7. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.
Hart CL; Haney M; Vosburg SK; Comer SD; Foltin RW
Psychopharmacology (Berl); 2005 Sep; 181(2):237-43. PubMed ID: 15830233
[TBL] [Abstract][Full Text] [Related]
8. Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure.
Oliveto AH; Bickel WK; Kamien JB; Hughes JR; Higgins ST
Psychopharmacology (Berl); 1994 Apr; 114(3):417-23. PubMed ID: 7531852
[TBL] [Abstract][Full Text] [Related]
9. Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.
Lile JA; Kelly TH; Hays LR
Drug Alcohol Depend; 2012 Apr; 122(1-2):61-9. PubMed ID: 21975195
[TBL] [Abstract][Full Text] [Related]
10. Separate and combined effects of the GABA(B) agonist baclofen and Δ9-THC in humans discriminating Δ9-THC.
Lile JA; Kelly TH; Hays LR
Drug Alcohol Depend; 2012 Nov; 126(1-2):216-23. PubMed ID: 22699093
[TBL] [Abstract][Full Text] [Related]
11. Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.
Hunault CC; Böcker KB; Stellato RK; Kenemans JL; de Vries I; Meulenbelt J
Psychopharmacology (Berl); 2014 Dec; 231(24):4723-33. PubMed ID: 24879495
[TBL] [Abstract][Full Text] [Related]
12. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.
Lile JA; Kelly TH; Hays LR
Drug Alcohol Depend; 2011 Jul; 116(1-3):86-92. PubMed ID: 21227600
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).
Hunault CC; Mensinga TT; Böcker KB; Schipper CM; Kruidenier M; Leenders ME; de Vries I; Meulenbelt J
Psychopharmacology (Berl); 2009 May; 204(1):85-94. PubMed ID: 19099294
[TBL] [Abstract][Full Text] [Related]
14. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans.
Chait LD; Zacny JP
Psychopharmacology (Berl); 1992; 107(2-3):255-62. PubMed ID: 1319601
[TBL] [Abstract][Full Text] [Related]
15. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
Jones HE; Bigelow GE; Preston KL
J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
[TBL] [Abstract][Full Text] [Related]
16. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
17. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics.
Johnstone RE; Lief PL; Kulp RA; Smith TC
Anesthesiology; 1975 Jun; 42(6):674-84. PubMed ID: 48348
[TBL] [Abstract][Full Text] [Related]
18. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures.
Heishman SJ; Huestis MA; Henningfield JE; Cone EJ
Pharmacol Biochem Behav; 1990 Nov; 37(3):561-5. PubMed ID: 1965045
[TBL] [Abstract][Full Text] [Related]
19. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.
Haney M
Neuropsychopharmacology; 2007 Jun; 32(6):1391-403. PubMed ID: 17091128
[TBL] [Abstract][Full Text] [Related]
20. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.
Hunault CC; Mensinga TT; de Vries I; Kelholt-Dijkman HH; Hoek J; Kruidenier M; Leenders ME; Meulenbelt J
Psychopharmacology (Berl); 2008 Dec; 201(2):171-81. PubMed ID: 18695931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
